Welichem Biotech Inc. is a Canada-based drug discovery and early stage drug development company focusing on novel therapeutics for unmet medical needs including autoimmune and inflammatory diseases and cancers. The Company’s drug candidate, WBI-1001, was developed by the Company as a topical treatment for inflammatory skin diseases such as psoriasis and atopic dermatitis. It entered into an Asset Purchase Agreement with Stiefel, a Glaxo Group Limited company, for all the rights to the WBI-1001 technology. The Company’s other unique drug candidate, WBI-2100 and its analogous, which is in the pre-clinical stage of development, has unique dual activities of anti-cancer activity together with neutrophil boosting activity. Both WBI-1001 and WBI-2100 series compounds are derived from the metabolites of bacterial symbionts of soil living nematodes.